uniQure announces successful NASDAQ IPO - Gilde Healthcare

uniQure announces successful NASDAQ IPO

6. Februar 2014

Amsterdam, The Netherlands – uniQure, a Gilde Healthcare portfolio company, announced the pricing of its initial public offering of 5,400,000 ordinary shares at an initial public offering price of $17.00 per ordinary share raising $91.8 million and started trading under the symbol “QURE” on the NASDAQ Global Select Market on February 5, 2014. uniQure has granted the underwriters a 30-day option to purchase up to an additional 810,000 ordinary shares from uniQure at the public offering price, less underwriting discounts. After deducting the underwriting discounts and other estimated offering expenses payable by uniQure, the net proceeds of the initial public offering are expected to be approximately $81.9 million.
 
Proceeds of the initial public offering will be used for the commercialization of  Glybera® and further clinical development of uniQure’s product pipeline consisting of gene therapies for the treatment of Hemophilia B, Acute Intermittent Porphyria, Sanfilippo B Syndrome and Parkinson’s Disease.
 
Edwin de Graaf represented Gilde Healthcare on the company’s supervisory board and has worked closely with management to support the company’s corporate development since 2006. In this period the company built a platform to rapidly develop and manufacture gene therapies and received regulatory approval for Glybera®, the first gene therapy approved by the European Commission. 

About uniQure
uniQure is delivering on the promise of gene therapy, single treatments with potentially curative results. uniQure has developed a modular platform to rapidly bring new disease modifying therapies to patients with severe disorders. The approach is validated by multiple partnerships and the regulatory approval of lead product Glybera®. www.uniqure.com

About Gilde Healthcare
Gilde Healthcare (Utrecht, The Netherlands and Cambridge, USA) is a transatlantic growth capital investor focused on private healthcare companies. It has over €450 million ($600 million) under management and is actively looking to lead new investments in therapeutics, medical devices and healthcare services. For a list of Gilde’s portfolio companies please visit the website at www.gildehealthcare.com.

Gilde Healthcare company Moximed raises $40 Million to advance world’s first Implantable Shock Absorber for Knee Osteoarthritis

Moximed, a medical device company on a mission to improve the standard of care for people with knee osteoarthritis (OA), today announced $40 million in Series C equity and debt financing. The round was led...
16. August 2022

Gilde Healthcare company Nalu appoints Thomas West as new president and CEO

Nalu Medical, Inc. (“Nalu”), a private company focused on innovative and minimally invasive solutions for chronic neuropathic pain, announced that the Board of Directors has appointed Thomas “Tom” West as President and Chief Executive Officer....
19. Juli 2022

Gilde Healthcare bolsters its Private Equity team in Frankfurt office

Dutch sector specialist Gilde Healthcare announces two new hires to its private equity team in Germany, following the recent close of its new €518m lower mid-market fund Gilde Healthcare Private Equity IV. With the recruitment...
12. Juli 2022